Chadwick W Christine, MD
Neurology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
- Since medical school
- 35 years
- Js Weill Medical College, Cornell University, 1991
Offices
5 locations · UCSF Medical Group Business Services · University of California San Francisco
Hospitals listed: Marinhealth Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Christine’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G76788 · Current
Licensed to practise in California · since 1993 · expires 2027-05-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$45,842
Medicare paid this office $45,842 for 287 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 110 | $15,107 | $114 |
| Return visit (30+ min) | 139 | $14,054 | $76 |
| Short return visit (20+ min) | 100 | $6,191 | $50 |
| New patient visit (60+ min) | 23 | $3,546 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 158 | $3,375 | $14 |
See all 6 services
| Long return visit (40+ min) | 110 | $15,107 | $114 |
| Return visit (30+ min) | 139 | $14,054 | $76 |
| Short return visit (20+ min) | 100 | $6,191 | $50 |
| New patient visit (60+ min) | 23 | $3,546 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 158 | $3,375 | $14 |
| New patient visit (45+ min) | 25 | $2,581 | $103 |
Who their Medicare patients are
287 Original Medicare patients in 2024. Average age 77 · Women 37% · Also on Medicaid 14% · Health risk score 1.49. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 61% · Depression 47% · Coronary heart disease 24% · Chronic kidney disease 17% · Dementia 17% · Diabetes 15% · Cancer 14% · Atrial fibrillation 14% · Heart failure 10% · COPD 9% · Stroke 9%.
The office billed $327,906, Medicare allowed $64,803 and paid $45,842; for 744 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 287 | 744 | 77 | 1.49 | $327,906 | $45,842 |
| 2023 | 289 | 534 | 77 | 1.44 | $324,789 | $44,288 |
| 2022 | 339 | 617 | 76 | 1.41 | $382,206 | $52,522 |
| 2021 | 407 | 692 | 76 | 1.36 | $488,689 | $68,677 |
| 2020 | 373 | 623 | 75 | 1.52 | $420,160 | $47,152 |
| 2019 | 423 | 768 | 75 | 1.57 | $524,967 | $60,296 |
| 2018 | 428 | 733 | 75 | 1.48 | $478,958 | $54,568 |
| 2017 | 432 | 773 | 74 | 1.54 | $480,661 | $60,699 |
| 2016 | 452 | 786 | 74 | 1.57 | $467,880 | $59,340 |
| 2015 | 468 | 839 | 73 | 1.61 | $509,064 | $65,597 |
| 2014 | 427 | 781 | 73 | 1.55 | $470,074 | $61,693 |
| 2013 | 398 | 698 | 73 | 1.46 | $366,757 | $48,039 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 111 | $16,644 | $112 |
| Return visit (30+ min) | 155 | $16,171 | $76 |
| Short return visit (20+ min) | 92 | $6,221 | $52 |
| New patient visit (60+ min) | 22 | $2,976 | $135 |
| New patient visit (45+ min) | 13 | $1,399 | $108 |
2022: 5 services
| Return visit (30+ min) | 204 | $22,878 | $77 |
| Long return visit (40+ min) | 116 | $16,713 | $113 |
| Short return visit (20+ min) | 92 | $5,587 | $49 |
| New patient visit (60+ min) | 28 | $4,461 | $159 |
| New patient visit (45+ min) | 21 | $2,398 | $114 |
2021: 5 services
| Long return visit (40+ min) | 184 | $29,606 | $114 |
| Return visit (30+ min) | 204 | $21,440 | $76 |
| New patient visit (60+ min) | 82 | $12,615 | $154 |
| New patient visit (45+ min) | 20 | $2,316 | $116 |
| Short return visit (20+ min) | 36 | $2,309 | $58 |
2020: 6 services
| Return visit (30+ min) | 256 | $22,530 | $60 |
| Long return visit (40+ min) | 79 | $8,378 | $89 |
| New patient visit (60+ min) | 62 | $8,021 | $129 |
| New patient visit (45+ min) | 12 | $1,145 | $95 |
| Return visit (30+ min) | 12 | $749 | $62 |
| Short return visit (20+ min) | 15 | $321 | $21 |
2019: 7 services
| Return visit (30+ min) | 256 | $24,663 | $62 |
| Long return visit (40+ min) | 130 | $12,681 | $77 |
| New patient visit (60+ min) | 58 | $8,352 | $144 |
| New patient visit (45+ min) | 20 | $2,089 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,962 | $93 |
| Short return visit (20+ min) | 31 | $1,517 | $43 |
| New patient visit (30+ min) | 13 | $883 | $68 |
2018: 4 services
| Return visit (30+ min) | 263 | $24,483 | $58 |
| Long return visit (40+ min) | 142 | $15,478 | $83 |
| New patient visit (60+ min) | 85 | $11,518 | $136 |
| New patient visit (45+ min) | 22 | $2,264 | $103 |
2017: 6 services
| Return visit (30+ min) | 235 | $21,461 | $58 |
| Long return visit (40+ min) | 161 | $17,518 | $85 |
| New patient visit (60+ min) | 69 | $9,778 | $142 |
| New patient visit (45+ min) | 36 | $3,630 | $101 |
| New patient visit (30+ min) | 13 | $881 | $68 |
| Short return visit (20+ min) | 16 | $683 | $43 |
2016: 8 services
| Return visit (30+ min) | 271 | $26,831 | $60 |
| Long return visit (40+ min) | 126 | $13,260 | $86 |
| New patient visit (60+ min) | 55 | $7,375 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,314 | $180 |
| New patient visit (45+ min) | 27 | $2,822 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,562 | $64 |
| New patient visit (30+ min) | 12 | $738 | $61 |
| Short return visit (20+ min) | 11 | $279 | $25 |
2015: 7 services
| Return visit (30+ min) | 288 | $31,814 | $62 |
| Long return visit (40+ min) | 112 | $12,625 | $90 |
| New patient visit (60+ min) | 81 | $11,305 | $140 |
| New patient visit (45+ min) | 25 | $2,678 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,325 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,040 | $65 |
| New patient visit (30+ min) | 14 | $890 | $64 |
2014: 6 services
| Return visit (30+ min) | 271 | $31,454 | $62 |
| New patient visit (60+ min) | 81 | $11,115 | $137 |
| Long return visit (40+ min) | 75 | $7,937 | $92 |
| New patient visit (45+ min) | 25 | $2,905 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,710 | $181 |
| Short return visit (20+ min) | 18 | $823 | $43 |
2013: 4 services
| Return visit (30+ min) | 282 | $30,535 | $58 |
| New patient visit (60+ min) | 68 | $9,187 | $135 |
| New patient visit (45+ min) | 39 | $4,302 | $110 |
| Long return visit (40+ min) | 27 | $2,377 | $88 |
Drugs they prescribed that Part D paid
$1,332,240
Pharmacies billed $1,332,240 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,728) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
3,294 generic and 434 brand-name prescriptions · $1,332,240 in drug cost · 246 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nuplazid | Parkinson's psychosis | 115 | $551,636 | $4,797 |
| Rytary | Parkinson's | 117 | $254,589 | $2,176 |
| Gocovri | None | 50 | $143,444 | $2,869 |
| Tolcapone | None | 12 | $61,218 | $5,102 |
| Nourianz | None | 23 | $57,739 | $2,510 |
See all 42 drugs
| Nuplazid | Parkinson's psychosis | 115 | $551,636 | $4,797 |
| Rytary | Parkinson's | 117 | $254,589 | $2,176 |
| Gocovri | None | 50 | $143,444 | $2,869 |
| Tolcapone | None | 12 | $61,218 | $5,102 |
| Nourianz | None | 23 | $57,739 | $2,510 |
| Rasagiline Mesylate | None | 178 | $44,653 | $251 |
| Carbidopa-Levodopa Er | None | 551 | $40,590 | $74 |
| Carbidopa-Levodopa | None | 630 | $35,488 | $56 |
| Carbidopa-Levodopa-Entacapone | None | 50 | $18,205 | $364 |
| Entacapone | None | 61 | $15,931 | $261 |
| Amantadine | None | 178 | $12,495 | $70 |
| Modafinil | None | 12 | $8,938 | $745 |
| Rivastigmine | None | 37 | $8,160 | $221 |
| Gabapentin | None | 185 | $4,279 | $23 |
| Donepezil | None | 308 | $3,916 | $13 |
| Ropinirole Er | None | 20 | $3,642 | $182 |
| Rivastigmine | None | 44 | $3,518 | $80 |
| Midodrine | None | 64 | $3,152 | $49 |
| Bupropion Xl | None | 74 | $2,061 | $28 |
| Ropinirole | None | 45 | $1,995 | $44 |
| Escitalopram | None | 97 | $1,878 | $19 |
| Mirtazapine | None | 78 | $1,874 | $24 |
| Pramipexole Dihydrochloride | None | 69 | $1,502 | $22 |
| Doxepin | None | 25 | $1,245 | $50 |
| Fludrocortisone Acetate | None | 21 | $1,178 | $56 |
| Quetiapine | None | 102 | $1,150 | $11 |
| Trazodone | None | 79 | $1,107 | $14 |
| Glycopyrrolate | None | 29 | $1,024 | $35 |
| Propranolol Hcl Er | None | 12 | $799 | $67 |
| Sertraline | None | 66 | $789 | $12 |
| Propranolol | None | 23 | $559 | $24 |
| Clozapine | None | 29 | $545 | $19 |
| Venlafaxine Hcl Er | None | 18 | $431 | $24 |
| Paroxetine | None | 16 | $421 | $26 |
| Primidone | None | 14 | $372 | $27 |
| Bupropion | None | 20 | $359 | $18 |
| Clonazepam | None | 46 | $326 | $7 |
| Citalopram Hbr | None | 38 | $288 | $8 |
| Zonisamide | None | 18 | $190 | $11 |
| Diazepam | None | 14 | $48 | $3 |
| Trihexyphenidyl | None | 13 | $33 | $3 |
| Lorazepam | None | 12 | $24 | $2 |
Year by year
| 2024 | 3,728 | 335 | 0% (0) | 12% | $1,332,240 |
| 2023 | 3,925 | 349 | 0% (0) | 11% | $1,381,734 |
| 2022 | 4,228 | 398 | 0% (0) | 10% | $1,314,769 |
| 2021 | 4,444 | 437 | 0% (0) | None | $1,070,859 |
| 2020 | 4,261 | 432 | 0% (0) | 10% | $1,002,824 |
| 2019 | 4,316 | 434 | 0% (0) | 11% | $946,697 |
| 2018 | 4,455 | 436 | 0% (0) | 13% | $1,028,340 |
| 2017 | 4,448 | 420 | None | 14% | $1,203,738 |
| 2016 | 4,536 | 401 | 0% (0) | 18% | $1,016,925 |
| 2015 | 4,202 | 395 | 0% (0) | 17% | $968,992 |
| 2014 | 3,438 | 349 | None | 17% | $629,327 |
| 2013 | 3,061 | 311 | 0% (0) | 17% | $519,196 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Nuplazid | Parkinson's psychosis | 105 | $488,053 | $4,648 |
| Rytary | Parkinson's | 96 | $238,339 | $2,483 |
| Gocovri | None | 44 | $135,978 | $3,090 |
| Tolcapone | None | 14 | $110,803 | $7,915 |
| Rasagiline Mesylate | None | 160 | $60,960 | $381 |
| Carbidopa-Levodopa Er | None | 602 | $52,949 | $88 |
| Carbidopa-Levodopa | None | 718 | $51,538 | $72 |
| Nourianz | None | 19 | $48,327 | $2,544 |
| Entacapone | None | 83 | $23,235 | $280 |
| Carbidopa-Levodopa-Entacapone | None | 62 | $22,679 | $366 |
| Myrbetriq | None | 17 | $21,173 | $1,245 |
| Amantadine | None | 208 | $18,245 | $88 |
| Pramipexole Er | None | 18 | $13,685 | $760 |
| Donepezil | None | 287 | $6,510 | $23 |
| Midodrine | None | 53 | $6,448 | $122 |
| Gabapentin | None | 181 | $4,789 | $26 |
| Ropinirole | None | 54 | $3,917 | $73 |
| Rivastigmine | None | 13 | $3,688 | $284 |
| Escitalopram | None | 165 | $2,846 | $17 |
| Trazodone | None | 97 | $2,832 | $29 |
| Mirtazapine | None | 84 | $2,756 | $33 |
| Pramipexole Dihydrochloride | None | 92 | $2,491 | $27 |
| Quetiapine | None | 92 | $1,971 | $21 |
| Modafinil | None | 12 | $1,858 | $155 |
| Glycopyrrolate | None | 42 | $1,852 | $44 |
| Propranolol | None | 42 | $1,846 | $44 |
| Fludrocortisone Acetate | None | 37 | $1,814 | $49 |
| Propranolol Hcl Er | None | 15 | $1,767 | $118 |
| Rivastigmine | None | 31 | $1,692 | $55 |
| Doxepin | None | 49 | $1,125 | $23 |
| Bupropion Xl | None | 35 | $854 | $24 |
| Baclofen | None | 17 | $824 | $48 |
| Citalopram Hbr | None | 50 | $599 | $12 |
| Sertraline | None | 45 | $548 | $12 |
| Primidone | None | 16 | $489 | $31 |
| Paroxetine | None | 23 | $416 | $18 |
| Venlafaxine Hcl Er | None | 20 | $311 | $16 |
| Bupropion | None | 18 | $240 | $13 |
| Clozapine | None | 32 | $176 | $5 |
| Clonazepam | None | 25 | $171 | $7 |
| Diazepam | None | 12 | $65 | $5 |
| Trihexyphenidyl | None | 12 | $55 | $5 |
2022: 44 drugs
| Nuplazid | Parkinson's psychosis | 88 | $382,624 | $4,348 |
| Rytary | Parkinson's | 109 | $231,346 | $2,122 |
| Tolcapone | None | 16 | $119,201 | $7,450 |
| Gocovri | None | 42 | $116,485 | $2,773 |
| Rasagiline Mesylate | None | 180 | $86,224 | $479 |
| Carbidopa-Levodopa Er | None | 709 | $60,574 | $85 |
| Carbidopa-Levodopa | None | 821 | $59,314 | $72 |
| Nourianz | None | 16 | $41,978 | $2,624 |
| Entacapone | None | 99 | $35,714 | $361 |
| Pramipexole Er | None | 48 | $25,295 | $527 |
| Carbidopa-Levodopa-Entacapone | None | 59 | $23,147 | $392 |
| Amantadine | None | 191 | $18,290 | $96 |
| Ongentys | None | 11 | $9,857 | $896 |
| Midodrine | None | 60 | $7,211 | $120 |
| Rivastigmine | None | 18 | $6,483 | $360 |
| Donepezil | None | 323 | $5,304 | $16 |
| Mirtazapine | None | 85 | $4,266 | $50 |
| Pramipexole Dihydrochloride | None | 105 | $4,018 | $38 |
| Escitalopram | None | 204 | $3,569 | $17 |
| Gabapentin | None | 135 | $3,565 | $26 |
| Propranolol | None | 38 | $3,215 | $85 |
| Ropinirole | None | 58 | $2,785 | $48 |
| Fludrocortisone Acetate | None | 53 | $2,597 | $49 |
| Quetiapine | None | 73 | $2,523 | $35 |
| Glycopyrrolate | None | 39 | $2,460 | $63 |
| Trazodone | None | 121 | $2,453 | $20 |
| Selegiline | None | 14 | $2,307 | $165 |
| Rivastigmine | None | 18 | $1,994 | $111 |
| Propranolol Hcl Er | None | 19 | $1,795 | $94 |
| Tizanidine | None | 12 | $1,313 | $109 |
| Baclofen | None | 23 | $1,103 | $48 |
| Bupropion Xl | None | 23 | $947 | $41 |
| Primidone | None | 21 | $890 | $42 |
| Paroxetine | None | 42 | $764 | $18 |
| Sertraline | None | 55 | $490 | $9 |
| Modafinil | None | 16 | $484 | $30 |
| Buspirone | None | 13 | $342 | $26 |
| Doxepin | None | 22 | $332 | $15 |
| Citalopram Hbr | None | 44 | $313 | $7 |
| Clonazepam | None | 30 | $312 | $10 |
| Venlafaxine Hcl Er | None | 13 | $204 | $16 |
| Diazepam | None | 20 | $129 | $6 |
| Trihexyphenidyl | None | 24 | $116 | $5 |
| Lorazepam | None | 13 | $46 | $4 |
2021: 42 drugs
| Nuplazid | Parkinson's psychosis | 62 | $249,847 | $4,030 |
| Rytary | Parkinson's | 125 | $208,503 | $1,668 |
| Rasagiline Mesylate | None | 195 | $103,847 | $533 |
| Carbidopa-Levodopa | None | 912 | $78,016 | $86 |
| Tolcapone | None | 18 | $69,237 | $3,846 |
| Carbidopa-Levodopa Er | None | 717 | $62,084 | $87 |
| Gocovri | None | 24 | $44,896 | $1,871 |
| Pramipexole Er | None | 55 | $32,751 | $595 |
| Carbidopa-Levodopa-Entacapone | None | 64 | $29,057 | $454 |
| Entacapone | None | 104 | $25,359 | $244 |
| Myrbetriq | None | 38 | $24,284 | $639 |
| Amantadine | None | 173 | $18,685 | $108 |
| Midodrine | None | 89 | $9,559 | $107 |
| Rivastigmine | None | 20 | $7,454 | $373 |
| Ropinirole Er | None | 20 | $5,189 | $259 |
| Mirtazapine | None | 117 | $4,558 | $39 |
| Donepezil | None | 295 | $4,359 | $15 |
| Quetiapine | None | 89 | $4,031 | $45 |
| Pramipexole Dihydrochloride | None | 134 | $3,977 | $30 |
| Gabapentin | None | 177 | $3,951 | $22 |
| Propranolol | None | 70 | $3,948 | $56 |
| Fludrocortisone Acetate | None | 59 | $3,108 | $53 |
| Escitalopram | None | 159 | $2,454 | $15 |
| Ropinirole | None | 53 | $2,335 | $44 |
| Rivastigmine | None | 23 | $2,121 | $92 |
| Glycopyrrolate | None | 38 | $2,067 | $54 |
| Propranolol Hcl Er | None | 22 | $1,805 | $82 |
| Trazodone | None | 120 | $1,637 | $14 |
| Atropine Sulfate | None | 12 | $1,574 | $131 |
| Tizanidine | None | 12 | $1,204 | $100 |
| Bupropion Xl | None | 20 | $892 | $45 |
| Zonisamide | None | 16 | $888 | $56 |
| Clozapine | None | 16 | $831 | $52 |
| Paroxetine | None | 44 | $733 | $17 |
| Baclofen | None | 27 | $703 | $26 |
| Citalopram Hbr | None | 61 | $503 | $8 |
| Primidone | None | 20 | $465 | $23 |
| Modafinil | None | 12 | $290 | $24 |
| Clonazepam | None | 30 | $220 | $7 |
| Sertraline | None | 18 | $160 | $9 |
| Trihexyphenidyl | None | 15 | $88 | $6 |
| Lorazepam | None | 11 | $24 | $2 |
2020: 43 drugs
| Nuplazid | Parkinson's psychosis | 49 | $172,840 | $3,527 |
| Tolcapone | None | 19 | $158,455 | $8,340 |
| Rytary | Parkinson's | 97 | $135,223 | $1,394 |
| Rasagiline Mesylate | None | 199 | $134,574 | $676 |
| Carbidopa-Levodopa | None | 908 | $62,996 | $69 |
| Carbidopa-Levodopa Er | None | 655 | $50,471 | $77 |
| Tetrabenazine | None | 11 | $33,679 | $3,062 |
| Carbidopa-Levodopa-Entacapone | None | 87 | $31,618 | $363 |
| Pramipexole Er | None | 56 | $29,184 | $521 |
| Entacapone | None | 100 | $27,885 | $279 |
| Amantadine | None | 220 | $21,001 | $95 |
| Myrbetriq | None | 23 | $18,245 | $793 |
| Nourianz | None | 11 | $16,318 | $1,483 |
| Midodrine | None | 98 | $10,251 | $105 |
| Rivastigmine | None | 15 | $5,397 | $360 |
| Pramipexole Dihydrochloride | None | 142 | $4,684 | $33 |
| Ropinirole Er | None | 29 | $4,526 | $156 |
| Mirtazapine | None | 117 | $3,654 | $31 |
| Fludrocortisone Acetate | None | 48 | $3,641 | $76 |
| Donepezil | None | 248 | $3,491 | $14 |
| Propranolol | None | 64 | $2,840 | $44 |
| Gabapentin | None | 165 | $2,705 | $16 |
| Glycopyrrolate | None | 54 | $2,668 | $49 |
| Selegiline | None | 12 | $2,079 | $173 |
| Ropinirole | None | 33 | $1,790 | $54 |
| Trazodone | None | 106 | $1,615 | $15 |
| Escitalopram | None | 118 | $1,559 | $13 |
| Modafinil | None | 13 | $1,244 | $96 |
| Quetiapine | None | 71 | $1,236 | $17 |
| Atropine Sulfate | None | 20 | $1,177 | $59 |
| Paroxetine | None | 54 | $1,127 | $21 |
| Clozapine | None | 23 | $1,079 | $47 |
| Tizanidine | None | 11 | $1,066 | $97 |
| Zonisamide | None | 26 | $999 | $38 |
| Baclofen | None | 24 | $740 | $31 |
| Primidone | None | 24 | $725 | $30 |
| Phenytoin Sodium Extended | None | 11 | $351 | $32 |
| Citalopram Hbr | None | 58 | $350 | $6 |
| Trihexyphenidyl | None | 25 | $329 | $13 |
| Pregabalin | None | 11 | $285 | $26 |
| Clonazepam | None | 27 | $247 | $9 |
| Venlafaxine Hcl Er | None | 18 | $180 | $10 |
| Lorazepam | None | 13 | $54 | $4 |
2019: 42 drugs
| Rasagiline Mesylate | None | 219 | $165,807 | $757 |
| Rytary | Parkinson's | 114 | $141,068 | $1,237 |
| Nuplazid | Parkinson's psychosis | 43 | $140,187 | $3,260 |
| Tolcapone | None | 18 | $115,926 | $6,440 |
| Carbidopa-Levodopa | None | 939 | $59,672 | $64 |
| Carbidopa-Levodopa Er | None | 672 | $47,450 | $71 |
| Carbidopa-Levodopa-Entacapone | None | 102 | $39,656 | $389 |
| Pramipexole Er | None | 54 | $32,052 | $594 |
| Entacapone | None | 114 | $28,977 | $254 |
| Amantadine | None | 203 | $27,380 | $135 |
| Myrbetriq | None | 35 | $22,969 | $656 |
| Midodrine | None | 69 | $8,536 | $124 |
| Rivastigmine | None | 13 | $6,296 | $484 |
| Pramipexole Dihydrochloride | None | 149 | $5,909 | $40 |
| Donepezil | None | 245 | $4,993 | $20 |
| Gabapentin | None | 178 | $4,369 | $25 |
| Mirtazapine | None | 106 | $3,110 | $29 |
| Propranolol | None | 71 | $2,835 | $40 |
| Selegiline | None | 13 | $2,613 | $201 |
| Trazodone | None | 130 | $2,432 | $19 |
| Fludrocortisone Acetate | None | 46 | $2,430 | $53 |
| Glycopyrrolate | None | 56 | $2,369 | $42 |
| Escitalopram | None | 94 | $1,882 | $20 |
| Quetiapine | None | 59 | $1,678 | $28 |
| Propranolol Hcl Er | None | 13 | $1,611 | $124 |
| Ropinirole | None | 40 | $1,591 | $40 |
| Tizanidine | None | 14 | $1,554 | $111 |
| Paroxetine | None | 75 | $1,400 | $19 |
| Modafinil | None | 12 | $1,351 | $113 |
| Ropinirole Er | None | 13 | $1,232 | $95 |
| Zonisamide | None | 18 | $1,048 | $58 |
| Baclofen | None | 27 | $802 | $30 |
| Levetiracetam | None | 13 | $766 | $59 |
| Venlafaxine Hcl Er | None | 31 | $553 | $18 |
| Phenytoin Sodium Extended | None | 16 | $502 | $31 |
| Citalopram Hbr | None | 54 | $378 | $7 |
| Bupropion Hcl Sr | None | 15 | $340 | $23 |
| Primidone | None | 13 | $246 | $19 |
| Trihexyphenidyl | None | 30 | $204 | $7 |
| Sertraline | None | 29 | $190 | $7 |
| Clonazepam | None | 19 | $91 | $5 |
| Lorazepam | None | 17 | $63 | $4 |
2018: 49 drugs
| Rasagiline Mesylate | None | 269 | $233,778 | $869 |
| Tolcapone | None | 22 | $176,505 | $8,023 |
| Rytary | Parkinson's | 98 | $114,894 | $1,172 |
| Carbidopa-Levodopa | None | 931 | $65,576 | $70 |
| Nuplazid | Parkinson's psychosis | 21 | $61,035 | $2,906 |
| Carbidopa-Levodopa Er | None | 728 | $50,666 | $70 |
| Carbidopa-Levodopa-Entacapone | None | 125 | $45,504 | $364 |
| Entacapone | None | 99 | $40,799 | $412 |
| Pramipexole Er | None | 48 | $31,707 | $661 |
| Amantadine | None | 209 | $31,462 | $151 |
| Myrbetriq | None | 35 | $23,603 | $674 |
| Azilect | None | 20 | $18,462 | $923 |
| Sinemet 25-100 | None | 16 | $9,445 | $590 |
| Rivastigmine | None | 17 | $8,710 | $512 |
| Pramipexole Dihydrochloride | None | 170 | $7,583 | $45 |
| Midodrine | None | 55 | $7,133 | $130 |
| Vesicare | None | 12 | $6,689 | $557 |
| Gabapentin | None | 169 | $4,868 | $29 |
| Ropinirole Er | None | 12 | $3,843 | $320 |
| Donepezil | None | 188 | $3,397 | $18 |
| Propranolol | None | 65 | $2,762 | $42 |
| Quetiapine | None | 70 | $2,442 | $35 |
| Escitalopram | None | 116 | $2,429 | $21 |
| Trazodone | None | 172 | $2,329 | $14 |
| Selegiline | None | 11 | $2,215 | $201 |
| Propranolol Hcl Er | None | 16 | $2,165 | $135 |
| Fludrocortisone Acetate | None | 55 | $2,064 | $38 |
| Rivastigmine | None | 21 | $1,861 | $89 |
| Mirtazapine | None | 65 | $1,707 | $26 |
| Glycopyrrolate | None | 37 | $1,542 | $42 |
| Paroxetine | None | 89 | $1,213 | $14 |
| Ropinirole | None | 38 | $1,182 | $31 |
| Tizanidine | None | 17 | $1,157 | $68 |
| Bupropion Hcl Sr | None | 14 | $1,017 | $73 |
| Bupropion Xl | None | 12 | $874 | $73 |
| Baclofen | None | 35 | $825 | $24 |
| Levetiracetam | None | 18 | $800 | $44 |
| Venlafaxine Hcl Er | None | 45 | $676 | $15 |
| Zonisamide | None | 12 | $635 | $53 |
| Primidone | None | 18 | $500 | $28 |
| Clozapine | None | 11 | $498 | $45 |
| Polyethylene Glycol 3350 | None | 15 | $346 | $23 |
| Citalopram Hbr | None | 55 | $342 | $6 |
| Phenytoin Sodium Extended | None | 12 | $326 | $27 |
| Modafinil | None | 13 | $198 | $15 |
| Sertraline | None | 22 | $166 | $8 |
| Trihexyphenidyl | None | 30 | $157 | $5 |
| Clonazepam | None | 21 | $131 | $6 |
| Lorazepam | None | 12 | $16 | $1 |
2017: 43 drugs
| Rasagiline Mesylate | None | 246 | $239,788 | $975 |
| Azilect | None | 85 | $106,455 | $1,252 |
| Rytary | Parkinson's | 90 | $96,052 | $1,067 |
| Tolcapone | None | 14 | $94,678 | $6,763 |
| Carbidopa-Levodopa-Entacapone | None | 115 | $70,434 | $612 |
| Carbidopa-Levodopa | None | 1,016 | $63,992 | $63 |
| Entacapone | None | 97 | $46,279 | $477 |
| Nuplazid | Parkinson's psychosis | 17 | $40,515 | $2,383 |
| Carbidopa-Levodopa Er | None | 586 | $37,791 | $64 |
| Amantadine | None | 221 | $34,405 | $156 |
| Pramipexole Er | None | 42 | $19,214 | $457 |
| Myrbetriq | None | 22 | $13,177 | $599 |
| Pramipexole Dihydrochloride | None | 219 | $8,755 | $40 |
| Vesicare | None | 18 | $6,779 | $377 |
| Midodrine | None | 53 | $6,771 | $128 |
| Donepezil | None | 250 | $4,093 | $16 |
| Ropinirole Er | None | 13 | $3,807 | $293 |
| Gabapentin | None | 148 | $2,971 | $20 |
| Trazodone | None | 172 | $2,322 | $13 |
| Mirtazapine | None | 73 | $2,133 | $29 |
| Ropinirole | None | 55 | $1,863 | $34 |
| Fludrocortisone Acetate | None | 42 | $1,720 | $41 |
| Escitalopram | None | 97 | $1,525 | $16 |
| Selegiline | None | 18 | $1,494 | $83 |
| Propranolol Hcl Er | None | 14 | $1,406 | $100 |
| Tizanidine | None | 13 | $1,319 | $101 |
| Glycopyrrolate | None | 29 | $1,305 | $45 |
| Memantine | None | 27 | $1,254 | $46 |
| Modafinil | None | 13 | $1,237 | $95 |
| Paroxetine | None | 86 | $1,086 | $13 |
| Primidone | None | 21 | $1,030 | $49 |
| Quetiapine | None | 90 | $988 | $11 |
| Venlafaxine Hcl Er | None | 53 | $854 | $16 |
| Propranolol | None | 32 | $720 | $23 |
| Bupropion Xl | None | 13 | $549 | $42 |
| Citalopram Hbr | None | 64 | $512 | $8 |
| Zonisamide | None | 12 | $421 | $35 |
| Amitriptyline | None | 13 | $363 | $28 |
| Phenytoin Sodium Extended | None | 11 | $305 | $28 |
| Baclofen | None | 15 | $246 | $16 |
| Sertraline | None | 24 | $170 | $7 |
| Rizatriptan | None | 12 | $89 | $7 |
| Clonazepam | None | 12 | $43 | $4 |
2016: 46 drugs
| Azilect | None | 349 | $412,220 | $1,181 |
| Entacapone | None | 117 | $61,953 | $530 |
| Rytary | Parkinson's | 63 | $58,725 | $932 |
| Carbidopa-Levodopa | None | 1,157 | $56,910 | $49 |
| Carbidopa-Levodopa-Entacapone | None | 109 | $43,844 | $402 |
| Amantadine | None | 209 | $32,886 | $157 |
| Carbidopa-Levodopa Er | None | 608 | $28,977 | $48 |
| Mirapex Er | None | 19 | $15,418 | $811 |
| Pramipexole Dihydrochloride | None | 244 | $14,461 | $59 |
| Requip Xl | None | 16 | $14,064 | $879 |
| Pramipexole Er | None | 21 | $13,974 | $665 |
| Neupro | None | 16 | $13,739 | $859 |
| Comtan | None | 13 | $11,844 | $911 |
| Myrbetriq | None | 27 | $9,961 | $369 |
| Ropinirole Er | None | 21 | $6,673 | $318 |
| Midodrine | None | 59 | $5,980 | $101 |
| Donepezil | None | 273 | $5,321 | $19 |
| Modafinil | None | 32 | $3,594 | $112 |
| Linzess | None | 11 | $3,587 | $326 |
| Propranolol Hcl Er | None | 30 | $3,307 | $110 |
| Selegiline | None | 23 | $3,124 | $136 |
| Gabapentin | None | 139 | $2,926 | $21 |
| Bystolic | None | 11 | $2,564 | $233 |
| Trazodone | None | 152 | $2,468 | $16 |
| Ropinirole | None | 61 | $2,456 | $40 |
| Memantine | None | 28 | $2,329 | $83 |
| Mirtazapine | None | 48 | $1,447 | $30 |
| Escitalopram | None | 74 | $1,352 | $18 |
| Fludrocortisone Acetate | None | 32 | $1,332 | $42 |
| Primidone | None | 38 | $1,291 | $34 |
| Quetiapine | None | 46 | $1,145 | $25 |
| Propranolol | None | 32 | $1,072 | $33 |
| Venlafaxine Hcl Er | None | 69 | $1,061 | $15 |
| Trospium Chloride | None | 13 | $793 | $61 |
| Amitriptyline | None | 22 | $665 | $30 |
| Bupropion Hcl Sr | None | 16 | $640 | $40 |
| Paroxetine | None | 57 | $575 | $10 |
| Levetiracetam | None | 16 | $556 | $35 |
| Zonisamide | None | 16 | $444 | $28 |
| Baclofen | None | 14 | $322 | $23 |
| Phenytoin Sodium Extended | None | 13 | $315 | $24 |
| Citalopram Hbr | None | 28 | $252 | $9 |
| Alprazolam | None | 11 | $155 | $14 |
| Sertraline | None | 15 | $115 | $8 |
| Rizatriptan | None | 11 | $100 | $9 |
| Clonazepam | None | 12 | $31 | $3 |
2015: 43 drugs
| Azilect | None | 319 | $322,795 | $1,012 |
| Tasmar | None | 22 | $251,795 | $11,445 |
| Carbidopa-Levodopa | None | 1,132 | $56,613 | $50 |
| Entacapone | None | 130 | $52,055 | $400 |
| Carbidopa-Levodopa-Entacapone | None | 96 | $44,221 | $461 |
| Rytary | Parkinson's | 48 | $38,105 | $794 |
| Amantadine | None | 210 | $37,613 | $179 |
| Carbidopa-Levodopa Er | None | 524 | $31,458 | $60 |
| Pramipexole Dihydrochloride | None | 249 | $16,474 | $66 |
| Pramipexole Er | None | 20 | $10,706 | $535 |
| Requip Xl | None | 15 | $10,565 | $704 |
| Mirapex Er | None | 13 | $8,215 | $632 |
| Ropinirole Er | None | 24 | $6,708 | $280 |
| Modafinil | None | 24 | $6,195 | $258 |
| Donepezil | None | 251 | $4,703 | $19 |
| Myrbetriq | None | 11 | $4,493 | $408 |
| Rivastigmine | None | 27 | $4,029 | $149 |
| Propranolol Hcl Er | None | 23 | $3,062 | $133 |
| Midodrine | None | 36 | $2,973 | $83 |
| Sinemet 25-100 | None | 11 | $2,629 | $239 |
| Selegiline | None | 11 | $2,407 | $219 |
| Tizanidine | None | 12 | $2,309 | $192 |
| Ropinirole | None | 58 | $2,096 | $36 |
| Gabapentin | None | 102 | $1,728 | $17 |
| Venlafaxine Hcl Er | None | 79 | $1,674 | $21 |
| Trazodone | None | 126 | $1,463 | $12 |
| Glycopyrrolate | None | 20 | $1,354 | $68 |
| Propranolol | None | 33 | $1,296 | $39 |
| Escitalopram | None | 59 | $1,038 | $18 |
| Quetiapine | None | 57 | $977 | $17 |
| Primidone | None | 26 | $933 | $36 |
| Zolmitriptan | None | 14 | $808 | $58 |
| Paroxetine | None | 66 | $776 | $12 |
| Mirtazapine | None | 30 | $741 | $25 |
| Fludrocortisone Acetate | None | 23 | $688 | $30 |
| Amitriptyline | None | 24 | $589 | $25 |
| Zolpidem | None | 13 | $465 | $36 |
| Bupropion Hcl Sr | None | 11 | $347 | $32 |
| Trihexyphenidyl | None | 26 | $310 | $12 |
| Phenytoin Sodium Extended | None | 13 | $294 | $23 |
| Citalopram Hbr | None | 26 | $222 | $9 |
| Clonazepam | None | 30 | $159 | $5 |
| Clopidogrel | None | 12 | $91 | $8 |
2014: 32 drugs
| Azilect | 302 | $255,930 | $847 |
| Tasmar | 26 | $83,856 | $3,225 |
| Carbidopa-Levodopa | 956 | $62,828 | $66 |
| Carbidopa-Levodopa-Entacapone | 77 | $40,330 | $524 |
| Entacapone | 70 | $30,164 | $431 |
| Amantadine | 146 | $27,828 | $191 |
| Carbidopa-Levodopa Er | 448 | $25,016 | $56 |
| Pramipexole Dihydrochloride | 223 | $13,481 | $60 |
| Mirapex Er | 14 | $11,819 | $844 |
| Ropinirole | 93 | $9,943 | $107 |
| Exelon | 11 | $8,390 | $763 |
| Rivastigmine | 19 | $5,382 | $283 |
| Donepezil | 206 | $4,969 | $24 |
| Quetiapine | 79 | $2,456 | $31 |
| Sinemet 25-100 | 11 | $2,142 | $195 |
| Midodrine | 19 | $2,134 | $112 |
| Paroxetine | 102 | $2,070 | $20 |
| Gabapentin | 89 | $1,861 | $21 |
| Propranolol Hcl Er | 12 | $1,447 | $121 |
| Escitalopram | 55 | $1,403 | $26 |
| Venlafaxine Hcl Er | 34 | $996 | $29 |
| Trazodone | 83 | $814 | $10 |
| Glycopyrrolate | 17 | $731 | $43 |
| Primidone | 13 | $692 | $53 |
| Mirtazapine | 32 | $638 | $20 |
| Fludrocortisone Acetate | 16 | $542 | $34 |
| Citalopram Hbr | 27 | $464 | $17 |
| Phenytoin Sodium Extended | 12 | $374 | $31 |
| Propranolol | 25 | $312 | $12 |
| Trihexyphenidyl | 23 | $241 | $10 |
| Clopidogrel | 15 | $195 | $13 |
| Clonazepam | 25 | $115 | $5 |
2013: 30 drugs
| Azilect | 246 | $183,729 | $747 |
| Carbidopa-Levodopa | 785 | $59,533 | $76 |
| Tasmar | 29 | $43,593 | $1,503 |
| Entacapone | 69 | $36,209 | $525 |
| Carbidopa-Levodopa-Entacapone | 50 | $32,597 | $652 |
| Amantadine | 135 | $27,201 | $201 |
| Carbidopa-Levodopa Er | 426 | $25,950 | $61 |
| Mirapex Er | 17 | $13,291 | $782 |
| Pramipexole Dihydrochloride | 222 | $11,834 | $53 |
| Requip Xl | 19 | $10,556 | $556 |
| Ropinirole | 88 | $9,827 | $112 |
| Stalevo 100 | 16 | $8,622 | $539 |
| Rivastigmine | 24 | $6,062 | $253 |
| Donepezil | 229 | $5,296 | $23 |
| Quetiapine | 43 | $5,132 | $119 |
| Escitalopram | 64 | $3,018 | $47 |
| Midodrine | 28 | $2,546 | $91 |
| Paroxetine | 74 | $1,393 | $19 |
| Gabapentin | 39 | $1,187 | $30 |
| Propranolol | 33 | $1,017 | $31 |
| Primidone | 21 | $735 | $35 |
| Citalopram Hbr | 44 | $679 | $15 |
| Mirtazapine | 47 | $664 | $14 |
| Tizanidine | 12 | $555 | $46 |
| Trazodone | 49 | $518 | $11 |
| Trihexyphenidyl | 32 | $340 | $11 |
| Fludrocortisone Acetate | 18 | $331 | $18 |
| Phenytoin Sodium Extended | 12 | $293 | $24 |
| Clopidogrel | 15 | $223 | $15 |
| Clonazepam | 20 | $100 | $5 |
Money from drug and device companies
$155 in 2024
| 2024 | 1 | 3 | None | $155 |
| 2019 | 1 | 1 | $25 | $25 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | None | $155 | 3 payments
|
See all 3 published payments
| Boston Scientific | Meals · 2024-10-02 | None | $21 |
| Boston Scientific | Meals · 2024-10-02 | None | $42 |
| Boston Scientific | Meals · 2024-10-02 | None | $92 |
See earlier years (2019)
2019: $25
| Acorda Therapeutics | Inbrija | $25 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Neurocrine Biosciences, Inc. · A Randomized, Placebo Surgery Controlled, Double-Blinded, Multi-Center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of Vy-Aadc02 in Advanced Parkinson?S Disease With Motor Fluctuations · 2020 | Their institution | $449,037 |
| Neurocrine Biosciences, Inc. · A Randomized, Placebo Surgery Controlled, Double-Blinded, Multi-Center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of Vy-Aadc02 in Advanced Parkinson'S Disease With Motor Fluctuations · 2019 | Their institution | $286,144 |
| Neurocrine Biosciences, Inc. · A Randomized, Placebo Surgery Controlled, Double-Blinded, Multi-Center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of Vy-Aadc02 in Advanced Parkinson?S Disease With Motor Fluctuations · 2021 | Their institution | $113,464 |
| Neurocrine Biosciences, Inc. · An Observational, Long-Term Extension Study for Participants of Prior Vy-Aadc01 Or Vy-Aadc01 Clinical Studies · 2019 | Their institution | $95,761 |
| Neurocrine Biosciences, Inc. · An Observational, Long-Term Extension Study for Participants of Prior Vy-Aadc01 Or Vy-Aadc01 Clinical Studies · 2020 | Their institution | $77,279 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 3657334, Long-Term Safety and Efficacy Follow-Up of Ab-1005 Gene Transfer Study Participants With Parkinsons Disease Or Multiple System Atrophy · 2025 | Their institution | $29,655 |
| Neurocrine Biosciences, Inc. · An Observational, Long-Term Extension Study for Participants of Prior Vy-Aadc01 Or Vy-Aadc01 Clinical Studies · 2021 | Their institution | $28,580 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1437186855
- Licence
- CA G76788California G76788: Current · expires 2027-05-31
- Trained
- Js Weill Medical College, Cornell University, 1991 · 35 years ago
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G767880
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 1635 Divisadero Street, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-06-28
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.